Viral Vector Core
What is the Viral Vector Core?
The Viral Vector Core (VVC) uses cutting edge technologies to create and produce a variety of high quality viral vectors. The goal is to provide investigators with the most suitable and efficient gene transfer vectors for their research applications.
The vectors are produced in a newly renovated facility with functionally specific cell culture and vector production suites where state of-the-art equipment is used for both production and purification. Vectors produced in the core include: AD, AAV, and Lenti/retro. VVC staff can assist investigators with the selection of a gene transfer vector, its design and potential applications.
Viral Vector Core at UMass
The Viral Vector Core (VVC) is a driving engine of gene therapy research at the GTC. The core uses cutting-edge technologies to create and produce a variety of high quality viral vectors. The goal of the VVC is to provide investigators at UMass Chan and other institutions with the most suitable and efficient gene transfer vectors for their research applications.
Services include:
- Consultation on gene transfer vector selection
- Design and application
- AdV vector creation and production
- AAV vector production
- Lentiviral vector production
- AAV neutralizing antibody screening and titration
We produce more than 900 rAAV vector batches a year, supporting UMass Chan investigators as well as external needs from academia and industry around the world.
AAV Large Scale Manufacturing Facility
Foreseeing the rapid advance in the number and breadth of preclinical stage research projects, UMass has partnered with Cytiva (formerly GE Healthcare) to produce large quantities of high-quality recombinant adeno-associated virus (rAAV) vectors for use in larger scale preclinical research endeavors. To learn more visit:
https://www.umassmed.edu/research/cores/raavmanufacturing/
UMass Chan Medical School is also in the preliminary planning stage for a human applications GMP facility to produce clinical grade viral vectors as well as nonviral nucleic acid therapeutics. More details will be added as this facility becomes operational.
VVC is also in the preliminary planning stage for a human applications GMP facility to produce clinical grade viral vectors. More details will be added as this facility becomes operational.
You can get more information on specific vectors, or to learn about the services provided by VVC, by contacting Guangping Gao at Guangping.Gao@umassmed.edu. For IBC related questions regarding Viruses produced at the VVC please follow link.
Learn more about the breakthrough research at the Horae GTC